Last updated: October 6, 2026
Risperdal, the brand name for risperidone, moved from a high-value atypical antipsychotic to a mature generic market after U.S. oral-tablet and solution exclusivity ended. Janssen’s commercial strategy shifted toward Risperdal Consta, a long-acting injectable formulation, while newer products such as Invega and Invega Sustenna captured part of the franchise’s clinical and commercial demand. Peak annual Risperdal-family sales were approximately $4 billion before generic erosion. Legal settlements, off-label-promotion claims, product-liability litigation, and patent expiry materially reduced the franchise’s value.
What is Risperdal and how is the product marketed?
Risperdal contains risperidone, a dopamine D2 and serotonin 5-HT2A receptor antagonist. The FDA approved oral Risperdal in 1993 for schizophrenia in adults. The label later expanded to bipolar mania and irritability associated with autistic disorder in pediatric patients.[1]
The franchise has included:
| Product |
Dosage form |
Primary commercial role |
Market status |
| Risperdal |
Tablets |
Original oral product |
Generic competition |
| Risperdal M-Tab |
Orally disintegrating tablet |
Differentiated oral delivery |
Generic competition |
| Risperdal Oral Solution |
Liquid formulation |
Pediatric and swallowing-related use |
Generic competition |
| Risperdal Consta |
Long-acting intramuscular injection |
Maintenance treatment |
Separate formulation and patent estate |
| Invega |
Paliperidone extended-release tablets |
Follow-on oral franchise |
Branded and generic competition |
| Invega Sustenna and related products |
Long-acting paliperidone injections |
Successor long-acting franchise |
Branded franchise with later exclusivity |
Risperdal was developed and commercialized by Janssen Pharmaceuticals, a Johnson & Johnson company. The active ingredient, risperidone, is chemically related to paliperidone, the active metabolite marketed in the Invega franchise.
How did Risperdal sales develop over time?
Risperdal reached blockbuster status through broad use in schizophrenia, bipolar disorder, and selected pediatric indications. U.S. and international sales expanded through the 1990s and early 2000s as physicians shifted from older typical antipsychotics to atypical agents.
Selected global sales reported by Johnson & Johnson are shown below. Reported figures vary by accounting period and whether the company grouped related products in its disclosures.
| Year |
Approximate Risperdal-family sales |
Main market condition |
| 2000 |
More than $2 billion |
Rapid atypical-antipsychotic adoption |
| 2004 |
Approximately $3 billion |
Broad branded penetration |
| 2005 |
Approximately $3.5 billion |
Mature blockbuster phase |
| 2006 |
Approximately $3.4 billion |
Competitive and legal pressure begins |
| 2007 |
Approximately $4 billion |
Near-peak commercial performance |
| 2008 |
Approximately $2.3 billion |
Generic oral risperidone entry |
| 2010 |
Approximately $2 billion |
Oral erosion offset partly by Consta |
| 2013 |
Approximately $1.3 billion |
Mature portfolio and litigation costs |
| 2015 onward |
Not consistently separately disclosed |
Revenue absorbed into broader reporting categories |
Johnson & Johnson’s filings show the commercial impact of generic competition after oral risperidone entered the U.S. market. The company continued to report meaningful sales from Risperdal Consta, but the long-acting product did not fully replace the revenue lost from oral tablets.[2]
What caused the Risperdal revenue decline?
Four factors drove the decline:
- Generic substitution. Oral risperidone tablets, orally disintegrating tablets, and oral solution faced low-cost alternatives.
- Class competition. Aripiprazole, quetiapine, olanzapine, ziprasidone, and later paliperidone competed for the same treatment categories.
- Safety and prescribing restrictions. Antipsychotic use in elderly patients with dementia-related psychosis carried an FDA boxed warning for increased mortality. Pediatric prescribing also faced heightened scrutiny.[1]
- Legal and reputational damage. Government investigations and product-liability claims affected prescribing behavior and generated major settlement costs.
The shift from Risperdal to Invega was strategically important. Paliperidone gave Janssen a successor molecule with extended-release oral and long-acting injectable formulations. That transition preserved part of the antipsychotic franchise but changed the revenue base from the original Risperdal brand.
When did Risperdal lose U.S. exclusivity?
The principal U.S. compound protection for risperidone expired in the late 2000s. FDA-approved generic risperidone products entered the market in 2008 after expiration of the relevant listed patents and pediatric exclusivity period.
The core patent history is generally summarized as follows:
| Patent or protection |
Subject matter |
Approximate U.S. status |
| U.S. Patent No. 4,804,663 |
Risperidone and related benzisoxazole compounds |
Expired in 2007 |
| U.S. Patent No. 5,158,952 |
Related risperidone compound and pharmaceutical claims |
Expired in 2008 |
| Pediatric exclusivity |
FDA-approved pediatric indications |
Extended applicable protection by six months |
| Oral formulation claims |
Tablets, orally disintegrating tablets, and liquid products |
Did not prevent broad generic entry after core expiry |
The timing permitted generic manufacturers to sell oral risperidone shortly after the main patent barriers expired. Teva, Mylan, Sandoz, Actavis, and other manufacturers participated in the generic market. Market prices declined sharply as additional ANDAs entered.
What patents protect Risperdal Consta?
Risperdal Consta uses microsphere-based delivery technology to release risperidone over an extended period after intramuscular injection. Its intellectual-property position was separate from the oral risperidone estate.
The Consta platform relied on formulation, manufacturing, and drug-delivery claims involving biodegradable polymer microspheres. Relevant protection included U.S. Patent No. 6,193,996, which covered long-acting injectable formulations involving risperidone and polymeric delivery systems. Other patents and regulatory exclusivities addressed formulation and manufacturing aspects.
| Protection category |
Commercial relevance |
| Risperidone compound patents |
Expired before or around the start of the Consta commercial period |
| Microsphere formulation patents |
Protected controlled release and injectable composition |
| Manufacturing-process claims |
Raised technical barriers for ANDA applicants |
| FDA exclusivity |
Applied separately from the original oral product |
| Trade secrets |
Relevant to microsphere production, particle-size control, and release profiles |
Consta’s patent position was stronger than the oral tablet position because a generic applicant had to reproduce a complex long-acting formulation, not merely the active ingredient. The resulting technical burden included microsphere loading, particle-size distribution, residual solvent control, injection performance, and release kinetics.
The presence of a complex formulation did not create perpetual exclusivity. Once relevant patents and regulatory protections expired, competitors could pursue abbreviated or hybrid regulatory pathways. Manufacturing complexity, however, reduced the speed and number of potential entrants.
What is the FDA regulatory status of Risperdal?
Risperdal is FDA-approved for:
- Schizophrenia in adults and adolescents;
- Acute manic or mixed episodes associated with bipolar I disorder;
- Irritability associated with autistic disorder in pediatric patients.
Risperdal Consta is approved for schizophrenia and maintenance treatment of bipolar I disorder as monotherapy or adjunctive therapy.[1]
The FDA approved generic risperidone tablets and other oral dosage forms through the ANDA pathway. Generic applicants had to demonstrate pharmaceutical equivalence and bioequivalence. Long-acting injectable alternatives face more complex development requirements because the dosage form has extended release and clinically relevant product-performance characteristics.
The FDA labeling also includes important risk controls:
- Increased mortality in elderly patients with dementia-related psychosis;
- Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis;
- Neuroleptic malignant syndrome;
- Tardive dyskinesia;
- Metabolic changes, including hyperglycemia, dyslipidemia, and weight gain;
- Hyperprolactinemia;
- Orthostatic hypotension and falls.
These warnings affected market positioning and contributed to a more selective prescribing environment.
What is the Orange Book status of Risperdal?
The Orange Book historically listed patents associated with Risperdal and Risperdal Consta, but the original oral products no longer have effective U.S. market exclusivity comparable to their launch period. The key distinction is between:
- Oral risperidone: Mature generic market with multiple approved suppliers.
- Risperdal Consta: Complex injectable product with a separate patent and manufacturing history.
- Invega products: Separate paliperidone patents, regulatory exclusivities, and litigation history.
Orange Book listings do not by themselves establish that a product has no competition. They identify patents that an ANDA applicant must address through certification. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed. The filing can trigger patent litigation and a 30-month stay of final FDA approval under the Hatch-Waxman framework.
Which companies challenged Risperdal patents?
Generic manufacturers challenged the oral risperidone estate as the market approached patent expiry. Teva, Mylan, Sandoz, and other ANDA sponsors were among the principal participants in the generic market.
The major commercial outcome was generic entry rather than a prolonged exclusivity extension. The oral product therefore followed the typical small-molecule lifecycle:
- Branded launch and rapid adoption;
- Patent and pediatric-exclusivity protection;
- ANDA challenges and Paragraph IV activity;
- Multiple generic launches;
- Rapid price compression;
- Residual branded sales concentrated in differentiated formulations.
The long-acting injectable market had a different competitive profile. Complex manufacturing and delivery requirements made Consta less vulnerable to immediate multi-source substitution than oral Risperdal.
What patent litigation and settlements affected Risperdal?
The most financially significant Risperdal legal matter was not a patent case. In 2013, Johnson & Johnson and Janssen agreed to pay approximately $2.2 billion to resolve U.S. criminal and civil allegations concerning Risperdal and other products. The allegations included off-label promotion and payment-related claims involving prescribing and formulary activity.[3]
Risperdal also generated extensive product-liability litigation involving gynecomastia, a condition involving abnormal breast tissue development in males. Jury verdicts, appeals, settlements, and reserve charges created continuing financial exposure. The litigation was separate from generic patent entry but affected the brand’s economics through legal costs, settlement payments, and reputational pressure.
Government and private litigation reduced the net value of the franchise in three ways:
- Direct settlement and defense costs;
- Lower prescribing in certain populations;
- Reduced flexibility for promotional and lifecycle-management programs.
How strong is the Risperdal patent estate?
The patent estate was strong during the branded launch period but weak as a long-term barrier after core compound patents expired.
| Factor |
Assessment |
| Core molecule protection |
No longer commercially meaningful in the U.S. |
| Oral dosage-form protection |
Insufficient to block broad generic competition |
| Pediatric exclusivity |
Valuable but time-limited |
| Consta formulation protection |
Stronger technical barrier than oral Risperdal |
| Manufacturing know-how |
Relevant for long-acting injectable competition |
| Method-of-use patents |
Limited ability to preserve the broad franchise after generic entry |
| International protection |
Varied by country and national patent expiry |
| Litigation leverage |
Greater for complex injectables than for oral tablets |
The estate’s principal weakness was dependence on an old small-molecule compound. Secondary patents could delay or narrow competition, but they could not preserve the original revenue level once generic manufacturers established supply.
How did Risperdal compare with competing antipsychotics?
| Drug |
Manufacturer or originator |
Formulation strategy |
Commercial effect on Risperdal |
| Risperdal |
Janssen |
Oral and long-acting risperidone |
Original franchise |
| Invega |
Janssen |
Extended-release paliperidone |
Successor and partial cannibalization |
| Abilify |
Otsuka/Bristol Myers Squibb |
Oral and long-acting aripiprazole |
Major class competitor |
| Seroquel |
AstraZeneca |
Immediate- and extended-release quetiapine |
Broad competitive pressure |
| Zyprexa |
Eli Lilly |
Oral and injectable olanzapine |
Competing atypical antipsychotic |
| Geodon |
Pfizer |
Oral and injectable ziprasidone |
Smaller class competitor |
Invega was the most strategically important competitor to Risperdal because it came from the same corporate portfolio and supported a lifecycle transition. The active metabolite relationship allowed Janssen to retain clinical familiarity while introducing extended-release and long-acting products.
Abilify and Seroquel imposed the greatest external commercial pressure. Their indications, tolerability profiles, dosing schedules, and physician familiarity affected treatment selection before and after generic risperidone entry.
What generic entry risks exist for Risperdal?
For oral Risperdal, generic entry risk is no longer a future event. It is the central market condition. The primary risks are:
- Continued price compression;
- Substitution by pharmacy benefit managers;
- Reduced branded formulary access;
- Loss of routine maintenance prescriptions to generic risperidone;
- Limited ability to sustain premium pricing through brand recognition.
For Risperdal Consta, the risk is more dependent on technical and regulatory execution. A successful competitor would need to match the release profile, injection characteristics, dose delivery, and clinical performance of the microsphere product. That requirement supports higher barriers than those applicable to tablets, but it also increases the commercial value of a successful generic or biosimilar-like complex injectable entrant.
Risperdal is a small-molecule product, so it does not face biosimilar competition in the legal sense. Biosimilar risk applies to biologics. Consta may face complex-generic or follow-on injectable competition, but those products are not biosimilars.
What licensing deals supported the Risperdal franchise?
Risperdal was primarily an internally developed and commercialized Janssen product. Its major value drivers were internal discovery, clinical development, regulatory expansion, and lifecycle management rather than a high-profile external licensing transaction.
The more important commercial strategy was portfolio migration:
- Risperdal established the risperidone franchise.
- Risperdal Consta extended the product into long-acting treatment.
- Invega transferred patients and prescriber relationships to paliperidone.
- Invega Sustenna and later long-acting products preserved injectable-market exposure.
This strategy reduced the revenue shock from oral generic entry but also shifted sales from the original product to successor brands.
What is the current commercial outlook for Risperdal?
Risperdal’s oral products are mature, low-growth generic-market products. Their commercial value lies in unit volume, low manufacturing cost, and established clinical use rather than pricing power.
Risperdal Consta retains a differentiated role where clinicians value a long-acting risperidone formulation. Its outlook depends on:
- Availability and pricing of competing long-acting antipsychotics;
- Patient adherence requirements;
- Reimbursement for injectable administration;
- Provider preference for paliperidone or aripiprazole alternatives;
- Any approved complex-generic competitor;
- Janssen’s ability to maintain supply and clinical support.
The franchise’s historical revenue peak is not recoverable through the original oral products. The remaining value is concentrated in residual branded injectable demand, international sales, and any markets where generic penetration remains limited.
Key Takeaways
- Risperdal was one of the leading atypical antipsychotics and reached approximately $4 billion in annual sales before generic erosion.
- U.S. oral risperidone patents expired in the late 2000s, with generic entry beginning in 2008.
- Oral Risperdal now has limited brand-driven pricing power.
- Risperdal Consta had a stronger formulation and manufacturing barrier than oral risperidone.
- Invega and its long-acting products became the principal successor franchise.
- The $2.2 billion 2013 Johnson & Johnson settlement materially affected the product’s financial history.
- Risperdal is not subject to biosimilar competition because risperidone is a small molecule.
- The remaining commercial opportunity is concentrated in differentiated injectable treatment, international markets, and residual branded demand.
FAQs About Risperdal Market Exclusivity and Commercial Value
When did generic risperidone first enter the U.S. market?
Generic oral risperidone entered the U.S. market in 2008 after expiration of the principal compound and related patent protections, including applicable pediatric exclusivity.
Is Risperdal Consta still protected by patents?
The original Consta formulation was protected by patents covering long-acting risperidone delivery and microsphere technology. The commercial significance of those patents depends on the specific country, listed patent, regulatory pathway, and status of any follow-on injectable product.
Did Risperdal lose exclusivity before Invega launched?
No. Invega launched before the full commercial impact of oral Risperdal generic entry. Janssen used Invega and later long-acting paliperidone products as successor products during the Risperdal lifecycle transition.
Can a generic company substitute risperidone for Risperdal Consta automatically?
No. Generic oral risperidone is not therapeutically interchangeable with Risperdal Consta. Consta is a long-acting injectable dosage form with different administration, release characteristics, and clinical use.
What was the largest financial penalty associated with Risperdal?
The largest widely reported government resolution was the approximately $2.2 billion 2013 Johnson & Johnson and Janssen settlement involving Risperdal and other products. It resolved criminal and civil allegations related primarily to marketing and promotional conduct.[3]
References
- U.S. Food and Drug Administration. (2023). Risperdal (risperidone) prescribing information. FDA.
- Johnson & Johnson. (2000-2015). Annual reports and Form 10-K filings. Johnson & Johnson.
- U.S. Department of Justice. (2013, November 4). Johnson & Johnson to pay more than $2.2 billion to resolve criminal and civil investigations. U.S. Department of Justice.
- U.S. Patent and Trademark Office. (1989). U.S. Patent No. 4,804,663: Benzisoxazole derivatives.
- U.S. Patent and Trademark Office. (1992). U.S. Patent No. 5,158,952: Substituted benzisoxazole derivatives.
- U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,193,996: Long-acting injectable formulations.
